T1	p 43 121	early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy .
T2	p 197 217	diabetic nephropathy
T3	p 320 354	Type 2 diabetic patients ( N.=57 )
T4	p 387 403	with nephropathy
T5	p 406 413	N.=27 )
T6	p 426 437	nephropathy
T7	p 446 470	) . Diabetic nephropathy
T8	p 1355 1356	2
T9	p 1366 1400	mellitus patients with nephropathy
T10	i 101 119	pyridoxine therapy
T11	i 248 311	thiamine ( vitamin B1 ) and pyridoxine ( vitamin B6 ) therapy .
T12	i 505 517	B6 ( N.=12 )
T13	i 520 551	250 mg/day ) or B1+B6 ( N.=15 )
T14	i 572 573	)
T15	o 6 25	Plasma AGE-peptides
T16	o 30 39	C-peptide
T17	o 163 193	circulatory AGE-peptide levels
T18	o 206 217	nephropathy
T19	o 459 470	nephropathy
T20	o 653 766	glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal phosphate
T21	o 886 897	nephropathy
T22	o 984 995	nephropathy
T23	o 1196 1241	increase in C-peptide ( P=0.006 , P=0.004 ) .
T24	o 1285 1304	plasma AGE-peptides
T25	o 1529 1541	AGE-peptides
T26	o 1608 1619	C-peptide .